Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane)
Yazar
Soto, Alvaro Juarez
Gomes, Andrea Juliana Pereira de Santana
Given, Robert W.
Merseburger, Axel Stuart
Ozguroglu, Mustafa
Uemura, Hirotsugu
Ye, Dingwei
Londhe, Anil
Lopez-Gitlitz, Angela
McCarthy, Sharon Anne
Mundle, Suneel
Chi, Kim N.
Agarwal, Neeraj
Chowdhury, Simon
Bjartell, Anders
Chung, Byung Ha
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Bildiri [64839]